This site is intended for healthcare professionals
Drug news

Phase III success for eliglustat tartrate (Sanofi/Genzyme) in Gaucher Disease

Read time: 1 mins
Last updated:3rd Oct 2012
Published:3rd Oct 2012
Source: Pharmawand
ENGAGE, the first Phase III trial of the investigational oral therapy, eliglustat tartrate,from Sanofi/Genzyme, in previously untreated patients with Gaucher disease type 1, met its primary endpoint. Patients treated with eliglustat tartrate had a statistically significant improvement in spleen size at nine months, compared with placebo. Spleen volumes in eliglustat tartrate treated patients decreased from baseline by a mean of 28 percent versus a mean increase of two percent in placebo patients, for an absolute difference of 30 percent (p<0.0001). in addition, all secondary endpoints were met, including improvements in hemoglobin levels and platelet levels, as well as liver volumes compared with placebo-treated individuals.the initial safety analysis from engage suggests that eliglustat tartrate was well tolerated. there were no serious adverse events reported in the primary analysis period.>

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.